Toshiyuki Asaki

Title: Toshiyuki Asaki: Innovator in Monoclonal Antibody Research

Introduction

Toshiyuki Asaki is a prominent inventor based in Amagasaki, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has the potential to impact the treatment of various medical conditions.

Latest Patents

Asaki holds a patent for a monoclonal antibody against Nav1.7. The objective of this invention is to provide a novel monoclonal antibody that can be utilized for treating or preventing pain and pruritus. The patent discloses a monoclonal antibody or its antibody fragment, characterized by specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. This innovation represents a significant advancement in pain management therapies.

Career Highlights

Toshiyuki Asaki is associated with Shionogi Company Limited, where he continues to advance his research and development efforts. His work at Shionogi has positioned him as a key figure in the pharmaceutical industry, focusing on innovative solutions for pain relief.

Collaborations

Asaki collaborates with notable colleagues, including Tatsuya Takahashi and Sosuke Yoneda. Their combined expertise enhances the research and development initiatives at Shionogi, fostering an environment of innovation.

Conclusion

Toshiyuki Asaki's contributions to monoclonal antibody research exemplify the importance of innovation in the medical field. His patent for a monoclonal antibody against Nav1.7 showcases his commitment to improving patient care through scientific advancements.